Strategic Acquisition NovelCath has been integrated into Cirtec Medical, reinforcing a broader capability in design, development, vertical integration, and full-device assembly for complex interventional devices. This presents cross-sale opportunities to customers seeking end-to-end manufacturing and outsourcing for minimally invasive catheter delivery systems.

Interventional Focus Specialization in minimally invasive delivery systems for Structural Heart, Electrophysiology, and Neurovascular applications positions the company to target hospitals and medical device firms expanding interventional portfolios. Potential upsell of additional manufacturing services such as extrusions, braiding, coiling, and in-house sub-assembly.

Full-Service Capabilities In-house extrusion, braiding, coil, and assembly capabilities align with customers needing vertical integration and supply chain resilience. Use this to approach firms seeking single-source partners for complex delivery systems and reduced time-to-market.

Tech & Compliance Readiness Utilize the existing tech stack and digital tooling (AWS, Salesforce Marketing Cloud, DocuSign, Re:amaze) to streamline customer interactions, e-commerce onboarding, and contract execution. Propose scalable digital collaboration and secure procurement workflows to target larger OEMs.

Growth Signals Revenue range indicates a small- to mid-market profile with potential for rapid growth through contract manufacturing for more complex devices. Target mid-market medical device OEMs and Tier 2 suppliers seeking capacity expansion, risk-sharing partnerships, and access to Cirtec’s broader interventional device expertise.